Compare AbCellera Biologics Inc (ABCL) vs C.H. Robinson Worldwide, Inc. (CHRW) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs C.H. Robinson Worldwide, Inc. — how do they compare? AbCellera Biologics Inc trades at $7.12 (market cap $2.35B), while C.H. Robinson Worldwide, Inc. trades at $188.58 (market cap $22.49B). The key difference: C.H. Robinson Worldwide, Inc. is far larger — about 9.6× AbCellera Biologics Inc's market cap, and C.H. Robinson Worldwide, Inc. pays a 1.32% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | CHRW | |
|---|---|---|
Market Cap | $2.35B | $22.49B |
Sector | Health | Industrials |
52-Week High | $8.12 | $200.59 |
52-Week Low | $2.78 | $96.82 |
Enterprise Value | $1.99B | $23.98B |
Dividend Yield | — | 1.32% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
CH Robinson Worldwide (CHRW) trades at $190.95, up 0.58% with a bullish technical outlook. The stock shows strong profitability with ROE of 34.84% and has beaten earnings estimates for three consecutive quarters. Recent acquisitions like DeSpir Logistics and AI technology launches position the company for growth in logistics efficiency. Valuation metrics appear elevated with P/E of 38.18, though revenue has declined from 2022 peaks to $16.23B in 2025.
The outlook remains positive with analyst consensus target of $198.83 representing 4% upside. Key opportunities include AI-driven supply chain optimization and industry consolidation benefits, while risks involve freight market volatility and competitive pressures. Cash flow generation remains healthy with $915M operating cash flow in 2025 supporting dividend payments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About C.H. Robinson Worldwide, Inc.
C.H. Robinson is a top-tier non-asset-based third-party logistics provider with a significant focus on domestic freight brokerage (57% of 2021 net revenue), which reflects mostly truck brokerage but also rail intermodal. Additionally, the firm also operates a large air and ocean forwarding division (34%), which has grown organically and via tuck-in acquisitions. The remainder of revenue consists of the European truck-brokerage division, transportation management services, and a legacy produce-sourcing operation.
Read more on CHRW →
